The use of fingolimod was associated with a lower rate of relapse and less accumulation of lesions on MRI compared with interferon beta-1a in paediatric patients with relapsing multiple sclerosis (MS), the phase III PARADIGMS study has shown.
applications approved by US FDA as of 1 - 15 September 2018 which includes New Molecular Entities (NMEs) and new
biologics. It does not include Tentative Approvals. Supplemental approvals
may have occurred since the original approval date.
The use of antidepressant drugs in pregnant women taking antiepileptic drugs (AEDs) does not appear to contribute to a significant increase in the risk of congenital malformations, as well as affect seizure control, a study has found.
Among obese and overweight adults with type 2 diabetes mellitus, women appear to be less likely than men to develop mild cognitive impairment, independent of traditional risk factors, a recent study has shown.
The Fibromyalgia Integrative Training for Teens (FIT Teens), which combines cognitive behavioural therapy (CBT) and a specialized neuromuscular exercise training, effectively reduces pain in adolescents with juvenile fibromyalgia (JFM), a recent study has shown.
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.